Ross Donehower

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Disorders

Concepts & Ideas

Procedures

Activities & Behaviors

Drug Evaluation

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Lin Jianqing; Gilbert Jill; Rudek Michelle A; Zwiebel James A; Gore Steve; Jiemjit Anchalee; Zhao Ming; Baker Sharyn D; Ambinder Richard F; Herman James G; Donehower Ross C; Carducci Michael A
A phase I dose-finding study of 5-azacytidine in combination with sodium phenylbutyrate in patients with refractory solid tumors.
Jimeno A; Chan A; Cusatis G; Zhang X; Wheelhouse J; Solomon A; Chan F; Zhao M; Cosenza S C; Ramana Reddy M V; Rudek M A; Kulesza P; Donehower R C; Reddy E P; Hidalgo M
Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay.
Jimeno Antonio; Li Jing; Messersmith Wells A; Laheru Daniel; Rudek Michelle A; Maniar Manoj; Hidalgo Manuel; Baker Sharyn D; Donehower Ross C
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Ross Donehower (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Lin Jianqing; Gilbert Jill; Rudek Michelle A; Zwiebel James A; Gore Steve; Jiemjit Anchalee; Zhao Ming; Baker Sharyn D; Ambinder Richard F; Herman James G; Donehower Ross C; Carducci Michael A
A phase I dose-finding study of 5-azacytidine in combination with sodium phenylbutyrate in patients with refractory solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(19):6241-9.
2009: Jimeno A; Chan A; Cusatis G; Zhang X; Wheelhouse J; Solomon A; Chan F; Zhao M; Cosenza S C; Ramana Reddy M V; Rudek M A; Kulesza P; Donehower R C; Reddy E P; Hidalgo M
Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay.
Oncogene 2009;28(4):610-8.
2008: Jimeno Antonio; Li Jing; Messersmith Wells A; Laheru Daniel; Rudek Michelle A; Maniar Manoj; Hidalgo Manuel; Baker Sharyn D; Donehower Ross C
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(34):5504-10.
2008: Messersmith Wells A; Jimeno Antonio; Ettinger David; Laheru Dan; Brahmer Julie; Lansey Dina; Khan Yasmin; Donehower Ross C; Elsayed Yusri; Zannikos Peter; Hidalgo Manuel
Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors.
Cancer chemotherapy and pharmacology 2008;63(1):181-8.
2008: Laheru Dan; Croghan Gary; Bukowski Ronald; Rudek Michelle; Messersmith Wells; Erlichman Charles; Pelley Robert; Jimeno Antonio; Donehower Ross; Boni Joseph; Abbas Richat; Martins Patricia; Zacharchuk Charles; Hidalgo Manuel
A phase I study of EKB-569 in combination with capecitabine in patients with advanced colorectal cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(17):5602-9.
2008: Jimeno Antonio; Rudek Michelle A; Kulesza Peter; Ma Wen Wee; Wheelhouse Jenna; Howard Anna; Khan Yasmin; Zhao Ming; Jacene Heather; Messersmith Wells A; Laheru Daniel; Donehower Ross C; Garrett-Mayer Elizabeth; Baker Sharyn D; Hidalgo Manuel
Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(25):4172-9.
2008: Herman Joseph M; Swartz Michael J; Hsu Charles C; Winter Jordan; Pawlik Timothy M; Sugar Elizabeth; Robinson Ray; Laheru Daniel A; Jaffee Elizabeth; Hruban Ralph H; Campbell Kurtis A; Wolfgang Christopher L; Asrari Fariba; Donehower Ross; Hidalgo Manuel; Diaz Luis A; Yeo Charles; Cameron John L; Schulick Richard D; Abrams Ross
Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(21):3503-10.
2008: Jimeno Antonio; Rudek Michelle A; Purcell Thomas; Laheru Daniel A; Messersmith Wells A; Dancey Janet; Carducci Michael A; Baker Sharyn D; Hidalgo Manuel; Donehower Ross C
Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors.
Cancer chemotherapy and pharmacology 2008;61(3):423-33.
2008: Jimeno A; Messersmith W A; Lee C K; Ma W W; Laheru D; Donehower R C; Baker S D; Hidalgo M
Phase I study of troxacitabine administered by continuous infusion in subjects with advanced solid malignancies.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19(2):374-9.
2007: Li Jing; Zhao Ming; Jimeno Antonio; He Ping; Ramana Reddy M V; Hidalgo Manuel; Donehower Ross C; Rudek Michelle A
Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate ON 01910.Na, a mitotic progression modulator, in human plasma.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2007;856(1-2):198-204.
2007: Hughes Michael A; Frassica Deborah A; Yeo Charles J; Riall Taylor S; Lillemoe Keith D; Cameron John L; Donehower Ross C; Laheru Daniel A; Hruban Ralph H; Abrams Ross A
Adjuvant concurrent chemoradiation for adenocarcinoma of the distal common bile duct.
International journal of radiation oncology, biology, physics 2007;68(1):178-82.
2007: Swartz Michael J; Hughes Michael A; Frassica Deborah A; Herman Joseph; Yeo Charles J; Riall Taylor S; Lillemoe Keith D; Cameron John L; Donehower Ross C; Laheru Daniel A; Hruban Ralph H; Abrams Ross A
Adjuvant concurrent chemoradiation for node-positive adenocarcinoma of the duodenum.
Archives of surgery (Chicago, Ill. : 1960) 2007;142(3):285-8.
2007: Messersmith Wells A; Rudek Michelle A; Baker Sharyn D; Zhao Ming; Collins Connie; Colevas A Dimitrios; Donehower Ross C; Carducci Michael A; Wolff Antonio C
Phase I study of continuous weekly dosing of dimethylamino benzoylphenylurea (BPU) in patients with solid tumours.
European journal of cancer (Oxford, England : 1990) 2007;43(1):78-86.
2007: Albers J; Chaudhry V; Cavaletti G; Donehower R
Interventions for preventing neuropathy caused by cisplatin and related compounds.
Cochrane database of systematic reviews (Online) 2007;(1):CD005228.
2006: Gilbert Jill; Carducci Michael A; Baker Sharyn D; Dees Elizabeth C; Donehower Ross
A Phase I study of the oral antimetabolite, CS-682, administered once daily 5 days per week in patients with refractory solid tumor malignancies.
Investigational new drugs 2006;24(6):499-508.
2006: Philip Philip A; Mahoney Michelle R; Allmer Cristine; Thomas James; Pitot Henry C; Kim George; Donehower Ross C; Fitch Tom; Picus Joel; Erlichman Charles
Phase II study of erlotinib in patients with advanced biliary cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(19):3069-74.
2006: Messersmith Wells A; Baker Sharyn D; Lassiter Lance; Sullivan Rana A; Dinh Kimberly; Almuete Virna I; Wright John J; Donehower Ross C; Carducci Michael A; Armstrong Deborah K
Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(4):1270-5.
2005: Philip Philip A; Mahoney Michelle R; Allmer Cristine; Thomas James; Pitot Henry C; Kim George; Donehower Ross C; Fitch Tom; Picus Joel; Erlichman Charles
Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(27):6657-63.
2005: Dees E Claire; Baker Sharyn D; O'Reilly Seamus; Rudek Michelle A; Davidson Susan B; Aylesworth Cheryl; Elza-Brown Kathy; Carducci Michael A; Donehower Ross C
A phase I and pharmacokinetic study of short infusions of UCN-01 in patients with refractory solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(2 Pt 1):664-71.
2004: Messersmith Wells A; Laheru Daniel A; Senzer Neil N; Donehower Ross C; Grouleff Paula; Rogers Theresa; Kelley Sean K; Ramies David A; Lum Bert L; Hidalgo Manuel
Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(19):6522-7.
2004: Wang Tian-Li; Diaz Luis A; Romans Katharine; Bardelli Alberto; Saha Saurabh; Galizia Gennaro; Choti Michael; Donehower Ross; Parmigiani Giovanni; Shih Ie-Ming; Iacobuzio-Donahue Christine; Kinzler Kenneth W; Vogelstein Bert; Lengauer Christoph; Velculescu Victor E
Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients.
Proceedings of the National Academy of Sciences of the United States of America 2004;101(9):3089-94.
2004: Rudek Michelle A; Donehower Ross C; Statkevich Paul; Batra Vijay K; Cutler David L; Baker Sharyn D
Temozolomide in patients with advanced cancer: phase I and pharmacokinetic study.
Pharmacotherapy 2004;24(1):16-25.
2003: Wolff Antonio C; Donehower Ross C; Carducci M Katherine; Carducci Michael A; Brahmer Julie R; Zabelina Yelena; Bradley Matthews O; Anthony Forrest H; Swindell Charles S; Witman Philip A; Webb Nigel L; Baker Sharyn D
Phase I study of docosahexaenoic acid-paclitaxel: a taxane-fatty acid conjugate with a unique pharmacology and toxicity profile.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(10 Pt 1):3589-97.
2003: Aklilu M; Kindler H L; Donehower R C; Mani S; Vokes E E
Phase II study of flavopiridol in patients with advanced colorectal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(8):1270-3.
2003: Stewart D J; Donehower R C; Eisenhauer E A; Wainman N; Shah A K; Bonfils C; MacLeod A R; Besterman J M; Reid G K
A phase I pharmacokinetic and pharmacodynamic study of the DNA methyltransferase 1 inhibitor MG98 administered twice weekly.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(5):766-74.
2003: Pili Roberto; Donehower Ross C
Is HIF-1 alpha a valid therapeutic target?
Journal of the National Cancer Institute 2003;95(7):498-9.
2003: Dees E Claire; Rowinsky Eric K; Noe Dennis A; O'Reilly Seamus; Adjei Alex A; Elza-Brown Kathy; Donehower Ross C
A phase I and pharmacologic study of pyrazoloacridine and cisplatin in patients with advanced cancer.
Investigational new drugs 2003;21(1):75-84.
2003: Sparreboom Alex; Wolff Antonio C; Verweij Jaap; Zabelina Yelena; van Zomeren Desiree M; McIntire Gregory L; Swindell Charles S; Donehower Ross C; Baker Sharyn D
Disposition of docosahexaenoic acid-paclitaxel, a novel taxane, in blood: in vitro and clinical pharmacokinetic studies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(1):151-9.
2002: Baker Sharyn D; Verweij Jaap; Rowinsky Eric K; Donehower Ross C; Schellens Jan H M; Grochow Louise B; Sparreboom Alex
Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001.
Journal of the National Cancer Institute 2002;94(24):1883-8.
2002: Carducci Michael A; Nelson Joel B; Bowling M Kathy; Rogers Theresa; Eisenberger Mario A; Sinibaldi Victoria; Donehower Ross; Leahy Terri L; Carr Robert A; Isaacson Jeffrey D; Janus Todd J; Andre Amy; Hosmane Balakrishna S; Padley Robert J
Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(8):2171-80.
2002: Gore Steven D; Weng Li-Jun; Figg William D; Zhai Suoping; Donehower Ross C; Dover George; Grever Michael R; Griffin Constance; Grochow Louise B; Hawkins Anita; Burks Kathleen; Zabelena Yelena; Miller Carole B
Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(4):963-70.
2002: Azuma R; Saeki M; Yamamoto Y; Hagiwara Y; Grochow L B; Donehower R C
Metabolism and urinary excretion of a new quinoline anticancer drug, TAS-103, in humans.
Xenobiotica; the fate of foreign compounds in biological systems 2002;32(1):63-72.
2002: Purcell W Thomas; Donehower Ross C
Evolving therapies: farnesyltransferase inhibitors.
Current oncology reports 2002;4(1):29-36.
2001: Heath E I; O'Reilly S; Humphrey R; Sundaresan P; Donehower R C; Sartorius S; Kennedy M J; Armstrong D K; Carducci M A; Sorensen J M; Kumor K; Kennedy S; Grochow L B
Phase I trial of the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced solid tumors.
Cancer chemotherapy and pharmacology 2001;48(4):269-74.
2001: Carducci M A; Gilbert J; Bowling M K; Noe D; Eisenberger M A; Sinibaldi V; Zabelina Y; Chen T L; Grochow L B; Donehower R C
A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(10):3047-55.
2001: O'Reilly S; Hartman N R; Bowling K M; Rowinsky E K; Donehower R C; Collins J; Strong J M
Bioavailability of penclomedine and systemic exposure to 4-O-demethylpenclomedine in patients receiving oral and intravenous penclomedine.
Cancer chemotherapy and pharmacology 2001;48(3):223-8.
2001: Gore S D; Weng L J; Zhai S; Figg W D; Donehower R C; Dover G J; Grever M; Griffin C A; Grochow L B; Rowinsky E K; Zabalena Y; Hawkins A L; Burks K; Miller C B
Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(8):2330-9.
2001: Gilbert J; Baker S D; Bowling M K; Grochow L; Figg W D; Zabelina Y; Donehower R C; Carducci M A
A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(8):2292-300.
2001: Bradley M O; Swindell C S; Anthony F H; Witman P A; Devanesan P; Webb N L; Baker S D; Wolff A C; Donehower R C
Tumor targeting by conjugation of DHA to paclitaxel.
Journal of controlled release : official journal of the Controlled Release Society 2001;74(1-3):233-6.
2001: Jaffee E M; Hruban R H; Biedrzycki B; Laheru D; Schepers K; Sauter P R; Goemann M; Coleman J; Grochow L; Donehower R C; Lillemoe K D; O'Reilly S; Abrams R A; Pardoll D M; Cameron J L; Yeo C J
Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(1):145-56.
2001: Lakhanpal S; Donehower R C; Rowinsky E K
Phase II study of 4-ipomeanol, a naturally occurring alkylating furan, in patients with advanced hepatocellular carcinoma.
Investigational new drugs 2001;19(1):69-76.
2000: Donehower R C
Role of oral chemotherapy in colorectal cancer.
Oncology (Williston Park, N.Y.) 2000;14(11A):243-5.
2000: Chakravarthy A; Abrams R A; Yeo C J; Korman L T; Donehower R C; Hruban R H; Zahurek M L; Grochow L B; O'Reilly S; Hurwitz H; Jaffee E M; Lillemoe K D; Cameron J L
Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: acceptable toxicity and suggestion of improved 1-year disease-free survival.
International journal of radiation oncology, biology, physics 2000;48(4):1089-96.
2000: Munver R; Donehower R C; Kronz J D; Polascik T J
HIV infection presenting as an unusually large pure yolk sac tumor of the testis.
The Journal of urology 2000;164(5):1653-4.
2000: Dees E C; Whitfield L R; Grove W R; Rummel S; Grochow L B; Donehower R C
A phase I and pharmacologic evaluation of the DNA intercalator CI-958 in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(10):3885-94.
2000: Baker S D; Diasio R B; O'Reilly S; Lucas V S; Khor S P; Sartorius S E; Donehower R C; Grochow L B; Spector T; Hohneker J A; Rowinsky E K
Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(4):915-26.
2000: Dees E C; O'Reilly S; Goodman S N; Sartorius S; Levine M A; Jones R J; Grochow L B; Donehower R C; Fetting J H
A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancer.
Cancer investigation 2000;18(6):521-9.
1999: Nelson J B; Chen R N; Bishoff J T; Oh W K; Kantoff P W; Donehower R C; Kavoussi L R
Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular tumors.
Urology 1999;54(6):1064-7.
1999: Mikhak B; Zahurak M; Abeloff M D; Fetting J H; Davidson N E; Donehower R C; Waterfield W; Kennedy M J
Long term follow-up of women treated with 16-week, dose-intensive adjuvant chemotherapy for high risk breast carcinoma.
Cancer 1999;85(4):899-904.
1999: Baker S D; Wirth M; Statkevich P; Reidenberg P; Alton K; Sartorius S E; Dugan M; Cutler D; Batra V; Grochow L B; Donehower R C; Rowinsky E K
Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(2):309-17.
1998: Gore S D; Rowinsky E K; Miller C B; Griffin C; Chen T L; Borowitz M; Donehower R C; Burks K L; Armstrong D K; Burke P J; Grever M R; Kaufmann S H
A phase II "window" study of topotecan in untreated patients with high risk adult acute lymphoblastic leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(11):2677-89.
1998: Jaffee E M; Abrams R; Cameron J; Donehower R; Duerr M; Gossett J; Greten T F; Grochow L; Hruban R; Kern S; Lillemoe K D; O'Reilly S; Pardoll D; Pitt H A; Sauter P; Weber C; Yeo C
A phase I clinical trial of lethally irradiated allogeneic pancreatic tumor cells transfected with the GM-CSF gene for the treatment of pancreatic adenocarcinoma.
Human gene therapy 1998;9(13):1951-71.
1998: Rowinsky E K; Baker S D; Burks K; O'Reilly S; Donehower R C; Grochow L B
High-dose topotecan with granulocyte-colony stimulating factor in fluoropyrimidine-refractory colorectal cancer: a phase II and pharmacodynamic study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9(2):173-80.
1998: Kennedy M J; Zahurak M L; Donehower R C; Noe D; Grochow L B; Sartorius S; Chen T L; Bowling K; Duerr M; Rowinsky E K
Sequence-dependent hematological toxicity associated with the 3-hour paclitaxel/cyclophosphamide doublet.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(2):349-56.
1998: O'Reilly S; Baker S D; Sartorius S; Rowinsky E K; Finizio M; Lubiniecki G M; Grochow L B; Gray J E; Pieniaszek H J; Donehower R C
A phase I and pharmacologic study of DMP 840 administered by 24-hour infusion.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9(1):101-4.
1997: Adjei A A; Budihardjo I I; Rowinsky E K; Kottke T J; Svingen P A; Buckwalter C A; Grochow L B; Donehower R C; Kaufmann S H
Cytotoxic synergy between pyrazoloacridine (NSC 366140) and cisplatin in vitro: inhibition of platinum-DNA adduct removal.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(5):761-70.
1997: O'Reilly S; Grochow L B; Donehower R C; Chen T L; Bowling K; Hartman N R; Struck R F; Rowinsky E K
Phase I and pharmacologic study of penclomedine, a novel alkylating agent, in patients with solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(5):1974-84.
1997: Rowinsky E K; Long G S; Noe D A; Grochow L B; Bowling M K; Sartorius S E; Donehower R C
Phase I and pharmacological study of CI-980, a novel synthetic antimicrotubule agent.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(3):401-7.
1996: Rowinsky E K; Kaufmann S H; Baker S D; Miller C B; Sartorius S E; Bowling M K; Chen T L; Donehower R C; Gore S D
A phase I and pharmacological study of topotecan infused over 30 minutes for five days in patients with refractory acute leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(12):1921-30.
1996: Kaufmann S H; Gore S D; Letendre L; Svingen P A; Kottke T; Buckwalter C A; Jones R J; Grochow L B; Burke P J; Donehower R C; Rowinsky E K
Factors affecting topotecan sensitivity in human leukemia samples.
Annals of the New York Academy of Sciences 1996;803():128-42.
1996: Baker S D; Khor S P; Adjei A A; Doucette M; Spector T; Donehower R C; Grochow L B; Sartorius S E; Noe D A; Hohneker J A; Rowinsky E K
Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(12):3085-96.
1996: Rowinsky E K; Kaufmann S H; Baker S D; Grochow L B; Chen T L; Peereboom D; Bowling M K; Sartorius S E; Ettinger D S; Forastiere A A; Donehower R C
Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(12):3074-84.
1996: O'Reilly S; Rowinsky E K; Slichenmyer W; Donehower R C; Forastiere A A; Ettinger D S; Chen T L; Sartorius S; Grochow L B
Phase I and pharmacologic study of topotecan in patients with impaired renal function.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(12):3062-73.
1996: O'Reilly S; Donehower R C; Rowinsky E K; Ord S; Grochow L B
A phase II trial of topotecan in patients with previously untreated pancreatic cancer.
Anti-cancer drugs 1996;7(4):410-4.
1996: O'Reilly S; Rowinsky E; Slichenmyer W; Donehower R C; Forastiere A; Ettinger D; Chen T L; Sartorius S; Bowling K; Smith J; Brubaker A; Lubejko B; Ignacio V; Grochow L B
Phase I and pharmacologic studies of topotecan in patients with impaired hepatic function.
Journal of the National Cancer Institute 1996;88(12):817-24.
1996: Kaufmann S H; Peereboom D; Buckwalter C A; Svingen P A; Grochow L B; Donehower R C; Rowinsky E K
Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines.
Journal of the National Cancer Institute 1996;88(11):734-41.
1996: Rowinsky E K; Grochow L B; Sartorius S E; Bowling M K; Kaufmann S H; Peereboom D; Donehower R C
Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(4):1224-35.
1996: O'Reilly S; Hartman N R; Grossman S A; Strong J M; Struck R F; Eller S; Lesser G J; Donehower R C; Rowinsky E K
Tissue and tumor distribution of C-penclomedine in rats.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(3):541-8.
1996: Kennedy M J; Zahurak M L; Donehower R C; Noe D A; Sartorius S; Chen T L; Bowling K; Rowinsky E K
Phase I and pharmacologic study of sequences of paclitaxel and cyclophosphamide supported by granulocyte colony-stimulating factor in women with previously treated metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(3):783-91.
1996: Donehower R C
The clinical development of paclitaxel: a successful collaboration of academia, industry and the National Cancer Institute.
Stem cells (Dayton, Ohio) 1996;14(1):25-8.
1996: Rowinsky E K; Lucas V S; Hsieh A L; Wargin W A; Hohneker J A; Lubejko B; Sartorius S E; Donehower R C
The effects of food and divided dosing on the bioavailability of oral vinorelbine.
Cancer chemotherapy and pharmacology 1996;39(1-2):9-16.
1995: Rowinsky E K; Noe D A; Grochow L B; Sartorious S E; Bowling M K; Chen T L; Lubejko B G; Kaufmann S H; Donehower R C
Phase I and pharmacologic studies of pyrazoloacridine, a novel DNA intercalating agent, on single-dosing and multiple-dosing schedules.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(8):1975-84.
1995: Kennedy M J; Donehower R C; Rowinsky E K
Treatment of metastatic breast cancer with combination paclitaxel/cyclophosphamide.
Seminars in oncology 1995;22(4 Suppl 8):23-7.
1995: Rowinsky E K; Donehower R C
Paclitaxel (taxol)
The New England journal of medicine 1995;332(15):1004-14.
1995: Baker S D; Grochow L B; Donehower R C
Should anticancer drug doses be adjusted in the obese patient?
Journal of the National Cancer Institute 1995;87(5):333-4.
1995: Berns A J; Clift S; Cohen L K; Donehower R C; Dranoff G; Hauda K M; Jaffee E M; Lazenby A J; Levitsky H I; Marshall F F
Phase I study of non-replicating autologous tumor cell injections using cells prepared with or without GM-CSF gene transduction in patients with metastatic renal cell carcinoma.
Human gene therapy 1995;6(3):347-68.
1995: Slichenmyer W J; Donehower R C
Recent clinical advances with camptothecin analogues.
Cancer treatment and research 1995;78():29-43.
1995: Slichenmyer W J; Donehower R C; Chen T L; Bowling M K; McGuire W P; Rowinsky E K
Pretreatment H2 receptor antagonists that differ in P450 modulation activity: comparative effects on paclitaxel clearance rates and neutropenia.
Cancer chemotherapy and pharmacology 1995;36(3):227-32.
1995: O'Reilly S; Kennedy M J; Rowinsky E K; Donehower R C
Vinorelbine and the topoisomerase 1 inhibitors: current and potential roles in breast cancer chemotherapy.
Breast cancer research and treatment 1995;33(1):1-17.
1994: Rowinsky E K; Adjei A; Donehower R C; Gore S D; Jones R J; Burke P J; Cheng Y C; Grochow L B; Kaufmann S H
Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(10):2193-203.
1994: Chaudhry V; Rowinsky E K; Sartorius S E; Donehower R C; Cornblath D R
Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies.
Annals of neurology 1994;35(3):304-11.
1994: Rowinsky E K; Grochow L B; Ettinger D S; Sartorius S E; Lubejko B G; Chen T L; Rock M K; Donehower R C
Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks.
Cancer research 1994;54(2):427-36.
1994: Borkowski J M; Duerr M; Donehower R C; Rowinsky E K; Chen T L; Ettinger D S; Grochow L B
Relation between age and clearance rate of nine investigational anticancer drugs from phase I pharmacokinetic data.
Cancer chemotherapy and pharmacology 1994;33(6):493-6.
1994: Rowinsky E K; Wright M; Monsarrat B; Donehower R C
Clinical pharmacology and metabolism of Taxol (paclitaxel): update 1993.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5 Suppl 6():S7-16.
1994: Slichenmyer W J; Rowinsky E K; Grochow L B; Kaufmann S H; Donehower R C
Camptothecin analogues: studies from the Johns Hopkins Oncology Center.
Cancer chemotherapy and pharmacology 1994;34 Suppl():S53-7.
1993: Donehower R C; Kirkwood J M
Therapeutic modalities.
Current opinion in oncology 1993;5(6):1001-4.
1993: Rowinsky E K; Chaudhry V; Forastiere A A; Sartorius S E; Ettinger D S; Grochow L B; Lubejko B G; Cornblath D R; Donehower R C
Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(10):2010-20.
1993: Rowinsky E K; Donehower R C
The clinical pharmacology of paclitaxel (Taxol).
Seminars in oncology 1993;20(4 Suppl 3):16-25.
1993: Rowinsky E K; Eisenhauer E A; Chaudhry V; Arbuck S G; Donehower R C
Clinical toxicities encountered with paclitaxel (Taxol).
Seminars in oncology 1993;20(4 Suppl 3):1-15.
1993: Peereboom D M; Donehower R C; Eisenhauer E A; McGuire W P; Onetto N; Hubbard J L; Piccart M; Gianni L; Rowinsky E K
Successful re-treatment with taxol after major hypersensitivity reactions.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(5):885-90.
1993: Rowinsky E K; Noe D A; Ettinger D S; Christian M C; Lubejko B G; Fishman E K; Sartorius S E; Boyd M R; Donehower R C
Phase I and pharmacological study of the pulmonary cytotoxin 4-ipomeanol on a single dose schedule in lung cancer patients: hepatotoxicity is dose limiting in humans.
Cancer research 1993;53(8):1794-801.
1993: Slichenmyer W J; Rowinsky E K; Donehower R C; Kaufmann S H
The current status of camptothecin analogues as antitumor agents.
Journal of the National Cancer Institute 1993;85(4):271-91.
1993: Donehower R C; Rowinsky E K
An overview of experience with TAXOL (paclitaxel) in the U.S.A.
Cancer treatment reviews 1993;19 Suppl C():63-78.
1993: Rowinsky E K; Citardi M J; Noe D A; Donehower R C
Sequence-dependent cytotoxic effects due to combinations of cisplatin and the antimicrotubule agents taxol and vincristine.
Journal of cancer research and clinical oncology 1993;119(12):727-33.
1993: Monsarrat B; Alvinerie P; Wright M; Dubois J; Guéritte-Voegelein F; Guénard D; Donehower R C; Rowinsky E K
Hepatic metabolism and biliary excretion of Taxol in rats and humans.
Journal of the National Cancer Institute. Monographs 1993;(15):39-46.
1993: Rowinsky E K; Chaudhry V; Cornblath D R; Donehower R C
Neurotoxicity of Taxol.
Journal of the National Cancer Institute. Monographs 1993;(15):107-15.
1993: Rowinsky E K; Wright M; Monsarrat B; Lesser G J; Donehower R C
Taxol: pharmacology, metabolism and clinical implications.
Cancer surveys 1993;17():283-304.
1992: Grochow L B; Rowinsky E K; Johnson R; Ludeman S; Kaufmann S H; McCabe F L; Smith B R; Hurowitz L; DeLisa A; Donehower R C
Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer.
Drug metabolism and disposition: the biological fate of chemicals 1992;20(5):706-13.
1992: Donehower R C
An overview of the clinical experience with hydroxyurea.
Seminars in oncology 1992;19(3 Suppl 9):11-9.
1992: Rowinsky E K; Conley B A; Jones R J; Spivak J L; Auerbach M; Donehower R C
Hexamethylene bisacetamide in myelodysplastic syndrome: effect of five-day exposure to maximal therapeutic concentrations.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1992;6(6):526-34.
1992: Hendricks C B; Rowinsky E K; Grochow L B; Donehower R C; Kaufmann S H
Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue.
Cancer research 1992;52(8):2268-78.
1991: Donehower R; Kirkwood J M
Therapeutic modalities.
Current opinion in oncology 1991;3(6):1035-6.
1991: Rowinsky E K; Donehower R C
Taxol: twenty years later, the story unfolds.
Journal of the National Cancer Institute 1991;83(24):1778-81.
1991: Hendricks C B; Grochow L B; Rowinsky E K; Forastiere A A; McGuire W P; Ettinger D S; Sartorius S; Lubejko B; Donehower R C
Phase I and pharmacokinetic study of hepsulfam (NSC 329680).
Cancer research 1991;51(21):5781-5.
1991: Rowinsky E K; Donehower R C
The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics.
Pharmacology & therapeutics 1991;52(1):35-84.
1991: Rowinsky E K; McGuire W P; Guarnieri T; Fisherman J S; Christian M C; Donehower R C
Cardiac disturbances during the administration of taxol.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1991;9(9):1704-12.
1991: Olivi A; Donehower R C; Mann R B; Brem H
Solitary, isolated metastasis from Ewing's sarcoma to the brain: case report.
Surgical neurology 1991;35(3):239-43.
1990: Rowinsky E K; Donehower R C; Spivak J L; Burke P J; Griffin C A; Jones R J
Effects of the differentiating agent hexamethylene bisacetamide on normal and myelodysplastic hematopoietic progenitors.
Journal of the National Cancer Institute 1990;82(24):1926-31.
1990: Donehower R C
Evaluating cancer chemotherapy by infusion.
Journal of the National Cancer Institute 1990;82(24):1867-8.
1990: Karp J E; Burke P J; Donehower R C
Effects of rhGM-CSF on intracellular ara-C pharmacology in vitro in acute myelocytic leukemia: comparability with drug-induced humoral stimulatory activity.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1990;4(8):553-6.
1990: Kennedy M J; Donehower R C; Grochow L B; Ettinger D S; Fetting J H; Abeloff M D
Phase II trial of menogaril as initial chemotherapy for metastatic breast cancer.
Investigational new drugs 1990;8(3):289-94.
1990: Rowinsky E K; Cazenave L A; Donehower R C
Taxol: a novel investigational antimicrotubule agent.
Journal of the National Cancer Institute 1990;82(15):1247-59.
1990: Weiss R B; Donehower R C; Wiernik P H; Ohnuma T; Gralla R J; Trump D L; Baker J R; Van Echo D A; Von Hoff D D; Leyland-Jones B
Hypersensitivity reactions from taxol.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1990;8(7):1263-8.
1990: Hantel A; Donehower R C; Rowinsky E K; Vance E; Clarke B V; McGuire W P; Ettinger D S; Noe D A; Grochow L B
Phase I study and pharmacodynamics of piroxantrone (NSC 349174), a new anthrapyrazole.
Cancer research 1990;50(11):3284-8.
1990: Abeloff M D; Beveridge R A; Donehower R C; Fetting J H; Davidson N E; Gordon G G; Waterfield W C; Damron D J
Sixteen-week dose-intense chemotherapy in the adjuvant treatment of breast cancer.
Journal of the National Cancer Institute 1990;82(7):570-4.
1990: Roberts J R; Allison D C; Donehower R C; Rowinsky E K
Development of polyploidization in taxol-resistant human leukemia cells in vitro.
Cancer research 1990;50(3):710-6.
1989: Rowinsky E K; Grochow L B; Hantel A; Ettinger D S; Vito B L; Donehower R C
Assessment of N-methylformamide (NMF) administered orally on a three times weekly schedule: a phase I study.
Investigational new drugs 1989;7(4):317-25.
1989: Roberts J R; Rowinsky E K; Donehower R C; Robertson J; Allison D C
Demonstration of the cell cycle positions of taxol-induced "asters" and "bundles" by sequential measurements of tubulin immunofluorescence, DNA content, and autoradiographic labeling of taxol-sensitive and -resistant cells.
The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 1989;37(11):1659-65.
1989: Clarke B V; Harwood K V; Donehower R
Local toxicity of piroxantrone: an anthrapyrazole with irritant and vesicant properties similar to those of doxorubicin.
Journal of the National Cancer Institute 1989;81(17):1331-2.
1989: McGuire W P; Rowinsky E K; Rosenshein N B; Grumbine F C; Ettinger D S; Armstrong D K; Donehower R C
Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms.
Annals of internal medicine 1989;111(4):273-9.
1989: Rowinsky E K; Burke P J; Karp J E; Tucker R W; Ettinger D S; Donehower R C
Phase I and pharmacodynamic study of taxol in refractory acute leukemias.
Cancer research 1989;49(16):4640-7.
1989: Hruban R H; Yardley J H; Donehower R C; Boitnott J K
Taxol toxicity. Epithelial necrosis in the gastrointestinal tract associated with polymerized microtubule accumulation and mitotic arrest.
Cancer 1989;63(10):1944-50.
1989: Karp J E; Donehower R C; Enterline J P; Dole G B; Fox M G; Burke P J
In vivo cell growth and pharmacologic determinants of clinical response in acute myelogenous leukemia.
Blood 1989;73(1):24-30.
1989: Grochow L B; Noe D A; Dole G B; Rowinsky E K; Ettinger D S; Graham M L; McGuire W P; Donehower R C
Phase I trial of trimetrexate glucuronate on a five-day bolus schedule: clinical pharmacology and pharmacodynamics.
Journal of the National Cancer Institute 1989;81(2):124-30.
1989: Grochow L B; Noe D A; Ettinger D S; Donehower R C
A phase I trial of trimetrexate glucuronate (NSC 352122) given every 3 weeks: clinical pharmacology and pharmacodynamics.
Cancer chemotherapy and pharmacology 1989;24(5):314-20.
1989: Ettinger D S; Finkelstein D M; Donehower R C; Chang A Y; Green M; Blum R; Hahn R G; Ruckdeschel J C
Phase II study of N-methylformamide, spirogermanium, and 4-demethoxydaunorubicin in the treatment of non-small cell lung cancer (EST 3583): an Eastern Cooperative Oncology Group study.
Medical and pediatric oncology 1989;17(3):197-201.
1988: Hantel A; Rowinsky E K; Noe D A; McGuire W P; Grochow L B; Vito B L; Ettinger D S; Donehower R C
Clinical and pharmacologic reappraisal of dichloromethotrexate.
Journal of the National Cancer Institute 1988;80(19):1547-53.
1988: Donehower R C
Understanding trimetrexate toxicity.
Journal of the National Cancer Institute 1988;80(16):1268-9.
1988: Rowinsky E K; Noe D A; Orr D W; Grochow L B; Ettinger D S; Donehower R C
Clinical pharmacology of oral and i.v. N-methylformamide: a pharmacologic basis for lack of clinical antineoplastic activity.
Journal of the National Cancer Institute 1988;80(9):671-8.
1988: Rowinsky E K; Donehower R C; Jones R J; Tucker R W
Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol.
Cancer research 1988;48(14):4093-100.
1988: Hantel A; Rowinsky E K; Donehower R C
Nifedipine and oncologic Raynaud phenomenon.
Annals of internal medicine 1988;108(5):767.
1987: Donehower R C; Rowinsky E K; Grochow L B; Longnecker S M; Ettinger D S
Phase I trial of taxol in patients with advanced cancer.
Cancer treatment reports 1987;71(12):1171-7.
1987: Rowinsky E K; Ettinger D S; McGuire W P; Noe D A; Grochow L B; Donehower R C
Prolonged infusion of hexamethylene bisacetamide: a phase I and pharmacological study.
Cancer research 1987;47(21):5788-95.
1987: Karp J E; Donehower R C; Burke P J
An in vitro model to predict clinical response in adult acute myelogenous leukemia.
Seminars in oncology 1987;14(2 Suppl 1):172-81.
1987: Donehower R C; Rosenshein N B; Rotmensch J; Ettinger D S
Sequential methotrexate and 5-fluorouracil in advanced ovarian carcinoma.
Gynecologic oncology 1987;27(1):90-6.
1987: Rowinsky E K; McGuire W P; Anhalt G J; Ettinger D S; Donehower R C
Hexamethylene bisacetamide-induced cutaneous vasculitis.
Cancer treatment reports 1987;71(5):471-4.
1987: Karp J E; Donehower R C; Dole G B; Burke P J
Correlation of drug-perturbed marrow cell growth kinetics and intracellular 1-B-D-arabinofuranosylcytosine metabolism with clinical response in adult acute myelogenous leukemia.
Blood 1987;69(4):1134-40.
1987: Brown T D; Donehower R C; Grochow L B; Rice A P; Ettinger D S
A phase I study of menogaril in patients with advanced cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1987;5(1):92-9.
1987: Longnecker S M; Donehower R C; Cates A E; Chen T L; Brundrett R B; Grochow L B; Ettinger D S; Colvin M
High-performance liquid chromatographic assay for taxol in human plasma and urine and pharmacokinetics in a phase I trial.
Cancer treatment reports 1987;71(1):53-9.
1986: Rowinsky E K; Ettinger D S; Grochow L B; Brundrett R B; Cates A E; Donehower R C
Phase I and pharmacologic study of hexamethylene bisacetamide in patients with advanced cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1986;4(12):1835-44.
1986: Eisenberger M; Hornedo J; Silva H; Donehower R; Spaulding M; Van Echo D
Carboplatin (NSC-241-240): an active platinum analog for the treatment of squamous-cell carcinoma of the head and neck.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1986;4(10):1506-9.
1986: Donehower R C; Karp J E; Burke P J
Pharmacology and toxicity of high-dose cytarabine by 72-hour continuous infusion.
Cancer treatment reports 1986;70(9):1059-65.
1986: Brown T D; Ettinger D S; Donehower R C
A phase I trial of spirohydantoin mustard (NSC 172112) in patients with advanced cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1986;4(8):1270-6.
1986: Olver I N; Donehower R C; Van Echo D A; Ettinger D S; Aisner J
Phase II trial of carboplatin in non-small cell lung cancer.
Cancer treatment reports 1986;70(3):421-2.
1985: Fetting J H; Wilcox P M; Sheidler V R; Enterline J P; Donehower R C; Grochow L B
Tastes associated with parenteral chemotherapy for breast cancer.
Cancer treatment reports 1985;69(11):1249-51.
1985: Ettinger D S; Orr D W; Rice A P; Donehower R C
Phase I study of N-methylformamide in patients with advanced cancer.
Cancer treatment reports 1985;69(5):489-93.
1984: Karp J E; Donehower R C; Dole G B; Burke P J
Direct relationship of marrow cell growth and 1-beta-D-arabinofuranosylcytosine metabolism.
Cancer research 1984;44(11):5046-50.
1984: Green L; Donehower R C
Hepatic toxicity of low doses of mithramycin in hypercalcemia.
Cancer treatment reports 1984;68(11):1379-81.
1984: Rotmensch J; Rosenshein N; Donehower R; Dillon M; Villar J
Plasma methotrexate levels in patients with gestational trophoblastic neoplasia treated by two methotrexate regimens.
American journal of obstetrics and gynecology 1984;148(6):730-4.
1982: Erlichman C; Donehower R C; Speyer J L; Klecker R; Chabner B A
Phase I-phase II trial of N-phosphonacetyl-L-aspartic acid given by intravenous infusion and 5-fluorouracil given by bolus injection.
Journal of the National Cancer Institute 1982;68(2):227-31.
1982: Liang C M; Donehower R C; Chabner B A
Biochemical interactions between N-(phosphonacetyl)-L-aspartate and 5-fluorouracil.
Molecular pharmacology 1982;21(1):224-30.
1982: Erlichman C; Donehower R C; Myers C E
Competitive protein binding assay of methotrexate.
Methods in enzymology 1982;84():447-58.
1982: Tester W J; Donehower R C; Eddy J L; Myers C E; Ihde D C
Evaluation of weekly escalating doses of dichloromethotrexate in patients with hepatocellular carcinoma and other solid tumors.
Cancer chemotherapy and pharmacology 1982;8(3):305-10.
1981: Chabner B A; Donehower R C; Schilsky R L
Clinical pharmacology of methotrexate.
Cancer treatment reports 1981;65 Suppl 1():51-4.
1980: Donehower R C; Allegra J C; Lippman M E; Chabner B A
Combined effects of methotrexate and 5-fluoropyrimidine on human breast cancer cells in serum-free culture.
European journal of cancer 1980;16(5):655-61.
1980: Donehower R C
Metabolic conversion of methotrexate in man.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1980;74():37-41.
1980: Erlichman C; Donehower R C; Chabner B A
The practical benefits of pharmacokinetics in the use of antineoplastic agents.
Cancer chemotherapy and pharmacology 1980;4(3):139-45.
1979: Donehower R C; Hande K R; Drake J C; Chabner B A
Presence of 2,4-diamino-N10-methylpteroic acid after high-dose methotrexate.
Clinical pharmacology and therapeutics 1979;26(1):63-72.
1979: Donehower R C; Myers C E; Chabner B A
New developments on the mechanisms of action of antineoplastic drugs.
Life sciences 1979;25(1):1-14.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Ross Donehower

Research Profile (preview)

Chemicals & Drugs

Disorders

Concepts & Ideas

Procedures

Activities & Behaviors

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Ross Donehower (preview)

All Publications